Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of “Moderate Buy” from Brokerages

Pulmonx Co. (NASDAQ:LUNG) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.75.

LUNG has been the topic of several research analyst reports. Citigroup restated a “neutral” rating and set a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th.

Insider Activity at Pulmonx

In related news, Director Glendon E. French III sold 55,453 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the sale, the director now directly owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. The trade was a 5.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel David Aaron Lehman sold 22,355 shares of Pulmonx stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.65, for a total transaction of $171,015.75. Following the sale, the general counsel now directly owns 175,496 shares of the company’s stock, valued at $1,342,544.40. This represents a 11.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,986 shares of company stock worth $986,673 over the last 90 days. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LUNG. Barclays PLC lifted its stake in Pulmonx by 1.8% in the third quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after buying an additional 1,679 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Pulmonx by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 315,532 shares of the company’s stock valued at $2,142,000 after acquiring an additional 2,363 shares during the period. Rhumbline Advisers boosted its stake in Pulmonx by 4.9% during the 4th quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock worth $363,000 after acquiring an additional 2,488 shares during the last quarter. American Century Companies Inc. boosted its stake in Pulmonx by 8.8% during the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock worth $236,000 after acquiring an additional 2,810 shares during the last quarter. Finally, 272 Capital LP acquired a new position in Pulmonx during the third quarter valued at approximately $25,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Price Performance

NASDAQ:LUNG opened at $7.48 on Monday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a market cap of $297.67 million, a PE ratio of -5.19 and a beta of 0.50. Pulmonx has a 12 month low of $5.46 and a 12 month high of $10.01. The company’s 50-day moving average price is $6.96 and its two-hundred day moving average price is $6.94.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.12. The business had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, equities analysts anticipate that Pulmonx will post -1.55 EPS for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.